ACHIEVE LIFE SCIENCES, INC.
ACHV · In Vitro & In Vivo Diagnostic Substances · 102.7M shares · +94%/yr ↑ dilution · EDGAR filings ↗
Reference price $2.92 · est. market cap ~$300M — last insider sale, 2025-09-18 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D46Clinical/early-stage biotech — deep losses but well-funded
Strengths
- Liquidity — current ratio 4.4 (80th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical/pipeline & funding risk — per 10-K
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Cash burnNegative free cash flow (-49.5M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +94%/yr over 3y (dilution, book value/share -64%)
- Notable holderHeld by 5 notable fund(s): STATE STREET CORP, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC +2 more (as of 2026-03-31)
- Trial resultTrial topline data reported — see 8-K for outcome 8-K ↗
Key metrics
Return on equity
-254.0%
Return on assets
-130.8%
Current ratio
4.4×
Free cash flow
-$49M
Tangible book value
$20M
Cash & investments
$36M
Cash runway
3q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2025-09-18 | Oki Mark K | Option exercise | 168K | — |
| 2025-09-18 | Oki Mark K | Sell | 50K | $2.92 |
| 2025-09-18 | Stewart Richard Alistair | Option exercise | 298K | — |
| 2025-09-18 | Stewart Richard Alistair | Sell | 130K | $2.92 |
| 2025-09-04 | Wan Jerry | Option exercise | 34K | — |
| 2025-09-04 | Wan Jerry | Sell | 14K | $2.77 |
| 2025-09-04 | KING THOMAS BRAXTON | Option exercise | 455K | — |
| 2025-09-04 | KING THOMAS BRAXTON | Sell | 140K | $2.77 |
| 2025-09-04 | JACOBS CINDY | Option exercise | 110K | — |
| 2025-09-04 | JACOBS CINDY | Sell | 28K | $2.77 |
| 2025-09-04 | Xinos Jaime | Option exercise | 69K | — |
| 2025-09-04 | Xinos Jaime | Sell | 21K | $2.77 |
| 2025-03-17 | Oki Mark K | Buy | 10K | $2.89 |
| 2025-03-17 | Stewart Richard Alistair | Buy | 10K | $2.86 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT01188187 ↗ | Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer Prostate Cancer | PHASE3 | Completed | 2014-02-01 |
| NCT01874561 ↗ | Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization Cardiac Conduction and Repolarization | PHASE1 | Completed | 2013-12-01 |
| NCT01497470 ↗ | A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen Cancer | PHASE1 | Completed | 2013-07-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Supply chain
Customers (0)
Suppliers (2)
- Adare Pharma Solutions
- Sopharma AD
Named in the 10-K; linked when we track them.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-02 | Exec/director change | filing ↗ |
| 2026-05-12 | ResultsExec/director changeExhibits | filing ↗ |
| 2026-04-16 | Material agreement3.02Exec/director changeReg FDExhibits | filing ↗ |
| 2026-03-24 | ResultsExhibits | filing ↗ |
| 2025-11-06 | ResultsExhibits | filing ↗ |
| 2025-10-07 | Exec/director change | filing ↗ |
| 2025-09-11 | Exec/director change | filing ↗ |
| 2025-08-07 | ResultsExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-02 | 2026-05-29 | 0001193125-26-252624 ↗ |
| 8-K | 2026-05-12 | 2026-05-07 | 0001193125-26-218175 ↗ |
| 10-Q | 2026-05-12 | 2026-03-31 | 0001193125-26-218177 ↗ |
| 10-K/A | 2026-04-30 | 2025-12-31 | 0001193125-26-197402 ↗ |
| 8-K | 2026-04-16 | 2026-04-15 | 0001193125-26-159189 ↗ |
| 8-K | 2026-03-24 | 2026-03-24 | 0001193125-26-120687 ↗ |
| 10-K | 2026-03-24 | 2025-12-31 | 0001193125-26-120690 ↗ |
| 10-Q | 2025-11-06 | 2025-09-30 | 0001193125-25-268074 ↗ |
| 8-K | 2025-11-06 | 2025-11-06 | 0001193125-25-268056 ↗ |
| 8-K | 2025-10-07 | 2025-10-06 | 0001193125-25-233581 ↗ |
| 8-K | 2025-09-11 | 2025-09-05 | 0001193125-25-201418 ↗ |
| 10-Q | 2025-08-07 | 2025-06-30 | 0000950170-25-104571 ↗ |